Advisors Capital Management LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.7% in the fourth quarter, Holdings Channel reports. The institutional investor owned 3,325 shares of the company’s stock after acquiring an additional 56 shares during the quarter. Advisors Capital Management LLC’s holdings in Eli Lilly and were worth $561,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently made changes to their positions in LLY. Price T Rowe Associates Inc. MD increased its holdings in shares of Eli Lilly and by 51.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,094,613 shares of the company’s stock worth $2,042,017,000 after buying an additional 4,082,728 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in Eli Lilly and in the 3rd quarter valued at approximately $194,874,000. Avidity Partners Management LP acquired a new stake in Eli Lilly and in the 4th quarter valued at approximately $136,845,000. Brandywine Global Investment Management LLC acquired a new stake in Eli Lilly and in the 4th quarter valued at approximately $132,324,000. Finally, Lord Abbett & CO. LLC acquired a new stake in Eli Lilly and in the 4th quarter valued at approximately $92,322,000. Institutional investors and hedge funds own 75.59% of the company’s stock.
In other news, major shareholder Lilly Endowment Inc sold 220,000 shares of Eli Lilly and stock in a transaction on Monday, January 11th. The shares were sold at an average price of $185.49, for a total transaction of $40,807,800.00. Following the completion of the sale, the insider now directly owns 111,003,815 shares of the company’s stock, valued at approximately $20,590,097,644.35. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders have sold 555,284 shares of company stock valued at $106,132,302. Corporate insiders own 0.09% of the company’s stock.
Several analysts recently weighed in on LLY shares. Wolfe Research upgraded shares of Eli Lilly and from a “peer perform” rating to an “outperform” rating and lifted their target price for the company from $147.00 to $183.00 in a report on Thursday, December 10th. Bank of America lifted their target price on shares of Eli Lilly and from $195.00 to $225.00 and gave the company a “buy” rating in a report on Friday, January 22nd. Barclays lifted their target price on shares of Eli Lilly and from $190.00 to $232.00 and gave the company an “overweight” rating in a report on Monday, February 1st. Morgan Stanley lifted their target price on shares of Eli Lilly and from $190.00 to $217.00 and gave the company an “overweight” rating in a report on Thursday, February 4th. Finally, Mizuho raised their price target on shares of Eli Lilly and from $222.00 to $228.00 and gave the company a “buy” rating in a research report on Monday, February 1st. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $193.88.
Eli Lilly and stock opened at $185.31 on Friday. The stock has a market cap of $177.71 billion, a P/E ratio of 30.28, a price-to-earnings-growth ratio of 1.57 and a beta of 0.37. The company has a fifty day simple moving average of $200.22 and a 200-day simple moving average of $169.29. Eli Lilly and Company has a 12-month low of $129.21 and a 12-month high of $218.00. The company has a current ratio of 1.36, a quick ratio of 1.06 and a debt-to-equity ratio of 3.27.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Thursday, January 28th. The company reported $2.75 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.35 by $0.40. The business had revenue of $7.44 billion during the quarter, compared to analysts’ expectations of $7.27 billion. Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. The company’s revenue for the quarter was up 21.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.73 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 7.56 earnings per share for the current fiscal year.
Eli Lilly and Profile
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Recommended Story: Asset Allocation, Balancing Your Investments
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.